Endo pre-empts sales slump with cost-cutting and reorganization
This article was originally published in Scrip
Endo Health Solutions is to slash its workforce by around 15%, about 700 positions, as it cuts costs ahead of generic competition for two if its biggest drugs.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.